Literature DB >> 9758595

An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.

A R Webster1, F M Richards, F E MacRonald, A T Moore, E R Maher.   

Abstract

von Hippel-Lindau disease (VHL) is a dominantly inherited familial cancer syndrome predisposing to ocular and CNS hemangioblastomas, renal-cell carcinoma (RCC), and pheochromocytoma. Both interfamilial and intrafamilial variability in expression is well recognized. Interfamilial differences in pheochromocytoma susceptibility have been attributed to allelic heterogeneity such that specific missense germ-line mutations confer a high risk for this complication. However, in most cases, tumor susceptibility does not appear to be influenced by the type of underlying VHL mutation. To probe the causes of phenotypic variation, we examined 183 individuals with germ-line VHL gene mutations, for the presence and number of ocular tumors. The prevalence of ocular angiomatosis did not increase with age, and the distribution of these tumors in gene carriers was significantly different than the expected stochastic distributions. Individuals with ocular hemangioblastomas had a significantly increased incidence of cerebellar hemangioblastoma and RCC (hazard ratios 2.3 and 4.0, respectively). The number of ocular tumors was significantly correlated in individuals of 12 degree relatedness but not in more distantly related individuals. These findings suggest that the development of VHL ocular tumors is determined at an early age and is influenced by genetic and/or environmental modifier effects that act at multiple sites. Functional polymorphisms in the glutathione-S-transferase M1 gene (GSTM1) or the cytochrome P450 2D6 gene (CYP2D6) did not show a significant association with the severity of ocular or renal involvement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758595      PMCID: PMC1377470          DOI: 10.1086/302037

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  36 in total

1.  Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.

Authors:  P A Crossey; K Foster; F M Richards; M E Phipps; F Latif; K Tory; M H Jones; E Bentley; R Kumar; M I Lerman
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

2.  Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

Authors:  J M Whaley; J Naglich; L Gelbert; Y E Hsia; J M Lamiell; J S Green; D Collins; H P Neumann; J Laidlaw; F P Li
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

3.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

4.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

Review 5.  Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility.

Authors:  C R Wolf; C A Smith; D Forman
Journal:  Br Med Bull       Date:  1994-07       Impact factor: 4.291

6.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

Authors:  P A Crossey; F M Richards; K Foster; J S Green; A Prowse; F Latif; M I Lerman; B Zbar; N A Affara; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

7.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas.

Authors:  H Kanno; K Kondo; S Ito; I Yamamoto; S Fujii; S Torigoe; N Sakai; M Hosaka; T Shuin; M Yao
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

8.  Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene.

Authors:  F M Richards; P A Crossey; M E Phipps; K Foster; F Latif; G Evans; J Sampson; M I Lerman; B Zbar; N A Affara
Journal:  Hum Mol Genet       Date:  1994-04       Impact factor: 6.150

9.  Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.

Authors:  K Foster; A Prowse; A van den Berg; S Fleming; M M Hulsbeek; P A Crossey; F M Richards; P Cairns; N A Affara; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1994-12       Impact factor: 6.150

10.  Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.

Authors:  W F Dietrich; E S Lander; J S Smith; A R Moser; K A Gould; C Luongo; N Borenstein; W Dove
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  23 in total

1.  Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier".

Authors:  Francesco Turturro
Journal:  J Mol Med (Berl)       Date:  2009-06       Impact factor: 4.599

Review 2.  Familial adult renal neoplasia.

Authors:  M Takahashi; R Kahnoski; D Gross; D Nicol; B T Teh
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

3.  Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only.

Authors:  F J Hes; S McKee; M J Taphoorn; P Rehal; R B van Der Luijt; R McMahon; J J van Der Smagt; D Dow; R A Zewald; J Whittaker; C J Lips; F MacDonald; P L Pearson; E R Maher
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

4.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

Authors:  Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

5.  Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.

Authors:  Brian C Toy; Elvira Agrón; Divya Nigam; Emily Y Chew; Wai T Wong
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079

6.  Von hippel-lindau disease.

Authors:  Frederik J Hes; Jo Wm Höppener; Rob B van der Luijt; Cornelis Jm Lips
Journal:  Hered Cancer Clin Pract       Date:  2005-11-15       Impact factor: 2.857

7.  A case of von Hippel-Lindau disease with exudative maculopathy.

Authors:  Basel T Ba Arah
Journal:  Oman J Ophthalmol       Date:  2009-05

8.  A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.

Authors:  Jing-Shan Huang; Chih-Ming Lin; Yu-Che Cheng; Kun-Long Hung; Chih-Cheng Chien; Shao-Kuan Chen; Chih-Ju Chang; Chan-Wei Chen; Chi-Jung Huang
Journal:  J Mol Med (Berl)       Date:  2009-03-14       Impact factor: 4.599

9.  Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.

Authors:  Raoul Hinze; Carsten Boltze; Axel Meye; Hans-Jürgen Holzhausen; Henning Dralle; Friedrich-Wilhelm Rath
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

10.  Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.

Authors:  Christopher Ricketts; Maurice P Zeegers; Jan Lubinski; Eamonn R Maher
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.